Girentuximab (G250) is a chimeric monoclonal antibody that binds carbonic anhydrase IX (CAIX), a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC)[1].
Molecular Weight:
(144.62 kDa)
Purity:
99.90
CAS Number:
[916138-87-9]
Target:
Carbonic Anhydrase
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted